The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy
- 232 Downloads
This study was prospectively carried out to clarify the effectiveness of visual and anatomical outcomes under combination therapy of intravitreal aflibercept (IVA) and verteporfin photodynamic therapy (vPDT) in over 24 months.
A single-arm prospective exploratory study.
Twenty-six eyes of 26 treatment naïve PCV patients were enrolled in this study. The primary outcome measures were the changes in best corrected visual acuity (BCVA) and the complete polyp regression rate. The secondary outcome measures included central retinal thickness assessed by optical coherence tomography.
The patients showed significant improvement in BCVA by 0.14 logMAR units at 12 months and 0.11 logMAR units at 24 months from baseline (both p < 0.01). The mean central retinal thickness also significantly decreased at 12 months (p < 0.001) and at 24 months (p = 0.001). Complete regression of polypoidal lesions was achieved by 15 out of 20 eyes (75%) at 12 months and 11 out of 20 eyes (55%) at 24 months. The mean treatment number was 2.9 courses of IVA and 1.5 courses of vPDT and the mean retreatment free interval after initial therapy was 12.8 months during follow up of 24 months. The complete data from all predetermined examinations were observed in 17 out of 26 enrolled patients (65%) in this study.
In this study, combination therapy of IVA and vPDT yielded visual and anatomical improvements in treatment-naïve PCV patients over a 24-month follow-up period.
KeywordsAflibercept Combination therapy Polypoidal choroidal vasculopathy PCV Photodynamic therapy
This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grant number JP16K11286 (S. Honda) and JSPS KAKENHI Grant number JP26861449 (W. Matsumiya)
Conflicts of interest
S. Nakai, None; W. Matsumiya, None; O. Keiko, None; A. Miki, None; M. Nakamura, None; S. Honda, None.
- 16.Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.CrossRefGoogle Scholar
- 18.Tang K, Si JK, Guo DD, Cui Y, Du YX, Pan XM, et al. Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and Meta-analysis. Int J Ophthalmol. 2015;18:1056–66.Google Scholar
- 24.Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:311–6.CrossRefGoogle Scholar
- 25.Takayama K, Kaneko H, Kataoka K, Hattori K, Ra E, Tsunekawa T, et al. Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: retrospective observation study. PLoS One. 2017. https://doi.org/10.1371/journal.pone.0176100.Google Scholar